BNTC vs. SPRO

Last updated Apr 1, 2026

Compare and contrast key facts about Benitec Biopharma Inc. (BNTC) and Spero Therapeutics, Inc. (SPRO).

Performance

BNTC vs. SPRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Benitec Biopharma Inc. (BNTC) and Spero Therapeutics, Inc. (SPRO). The values are adjusted to include any dividend payments, if applicable.

BNTC vs. SPRO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BNTC Benitec Biopharma Inc.	-20.94%	6.65%	291.02%	11.76%	-93.51%	-12.67%	-60.78%	-66.00%	-49.27%	5.71%
SPRO Spero Therapeutics, Inc.	0.43%	126.21%	-29.93%	-15.03%	-89.19%	-17.43%	101.66%	56.34%	-47.66%	2.17%

Fundamentals

EPS BNTC : -$1.23 SPRO : -$0.78
PS Ratio BNTC : 789.82 SPRO : 3.67
Total Revenue (TTM) BNTC : $556.00K SPRO : $35.77M
Gross Profit (TTM) BNTC : -$6.52K SPRO : -$72.47M
EBITDA (TTM) BNTC : -$55.03M SPRO : -$45.15M

Returns By Period

In the year-to-date period, BNTC achieves a -20.94% return, which is significantly lower than SPRO's 0.43% return.

BNTC

• 1D: 5.86%
• 1M: -2.29%
• YTD: -20.94%
• 6M: -24.09%
• 1Y: -18.14%
• 3Y*: 43.98%
• 5Y*: -35.95%
• 10Y*: -31.08%

SPRO

• 1D: 4.46%
• 1M: 7.83%
• YTD: 0.43%
• 6M: 24.47%
• 1Y: 225.00%
• 3Y*: 17.30%
• 5Y*: -30.35%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BNTC vs. SPRO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNTC

BNTC Risk / Return Rank: 27
BNTC Sharpe Ratio Rank: 28
BNTC Sortino Ratio Rank: 30
BNTC Omega Ratio Rank: 30
BNTC Calmar Ratio Rank: 24
BNTC Martin Ratio Rank: 25

SPRO

SPRO Risk / Return Rank: 90
SPRO Sharpe Ratio Rank: 72
SPRO Sortino Ratio Rank: 99
SPRO Omega Ratio Rank: 98
SPRO Calmar Ratio Rank: 94
SPRO Martin Ratio Rank: 87

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNTC vs. SPRO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Benitec Biopharma Inc. (BNTC) and Spero Therapeutics, Inc. (SPRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BNTC	SPRO	Difference
Sharpe ratio Return per unit of total volatility	-0.29	0.90	-1.19
Sortino ratio Return per unit of downside risk	0.00	6.29	-6.29
Omega ratio Gain probability vs. loss probability	1.00	1.78	-0.78
Calmar ratio Return relative to maximum drawdown	-0.53	5.16	-5.68
Martin ratio Return relative to average drawdown	-0.95	9.02	-9.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BNTC vs. SPRO - Sharpe Ratio Comparison

The current BNTC Sharpe Ratio is -0.29, which is lower than the SPRO Sharpe Ratio of 0.90. The chart below compares the historical Sharpe Ratios of BNTC and SPRO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BNTC	SPRO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.29	0.90	-1.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	-0.20	-0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.24	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	-0.14	-0.16

Correlation

The correlation between BNTC and SPRO is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BNTC vs. SPRO - Dividend Comparison

Neither BNTC nor SPRO has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018
BNTC Benitec Biopharma Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%
SPRO Spero Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

BNTC vs. SPRO - Drawdown Comparison

The maximum BNTC drawdown since its inception was -99.91%, roughly equal to the maximum SPRO drawdown of -97.46%. Use the drawdown chart below to compare losses from any high point for BNTC and SPRO.

Drawdown Indicators

	BNTC	SPRO	Difference
Max Drawdown Largest peak-to-trough decline	-99.91%	-97.46%	-2.45%
Max Drawdown (1Y) Largest decline over 1 year	-39.25%	-39.80%	+0.55%
Max Drawdown (5Y) Largest decline over 5 years	-98.05%	-97.13%	-0.92%
Max Drawdown (10Y) Largest decline over 10 years	-99.82%	—	—
Current Drawdown Current decline from peak	-99.50%	-89.40%	-10.10%
Average Drawdown Average peak-to-trough decline	-87.36%	-61.75%	-25.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.83%	22.77%	-0.94%

Volatility

BNTC vs. SPRO - Volatility Comparison

Benitec Biopharma Inc. (BNTC) has a higher volatility of 18.47% compared to Spero Therapeutics, Inc. (SPRO) at 13.13%. This indicates that BNTC's price experiences larger fluctuations and is considered to be riskier than SPRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BNTC	SPRO	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.47%	13.13%	+5.34%
Volatility (6M) Calculated over the trailing 6-month period	48.10%	32.66%	+15.44%
Volatility (1Y) Calculated over the trailing 1-year period	62.64%	252.14%	-189.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	102.83%	151.63%	-48.80%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	132.20%	125.84%	+6.36%

Financials